Anna Artigues-Adam

Valencia, VC 46010, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

AXL - a new player in resistance to HER2 blockade.

AXL - a new player in resistance to HER2 blockade.

Journal: Cancer treatment reviews
Published: July 26, 2023

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Journal: Cancers
Published: December 26, 2022

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.

Journal: Science advances
Published: May 20, 2022

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies.

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies.

Journal: Cancer communications (London, England)
Published: April 04, 2022

MicroRNAs as a clue to overcome breast cancer treatment resistance.

MicroRNAs as a clue to overcome breast cancer treatment resistance.

Journal: Cancer metastasis reviews
Published: August 14, 2021

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.

Journal: International journal of molecular sciences
Published: June 29, 2021

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.

Journal: Cancers
Published: May 13, 2021

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer.

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer.

Journal: ESMO open
Published: November 22, 2020

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.

Journal: International journal of molecular sciences
Published: September 17, 2020

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.

Journal: Frontiers in oncology
Published: January 01, 2020

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Journal: Scientific reports
Published: June 05, 2018

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

Journal: Scientific reports
Published: August 12, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026